|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | U.S. STEEL TOWER, FLOOR 60 |
Address2 | 600 GRANT STREET |
City | PITTSBURGH |
State | PA |
Zip Code | 15219 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 32065-12
|
||||||||
|
6. House ID# 314740000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: RYAN YUHAS |
Date | 1/20/2021 1:46:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital (DSH) cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Discuss issues related to Medicare accelerated payments with Congressional staff.
Discuss issues related to telehealth and HIT with Congressional staff.
Discuss the HEROES Act (H.R. 6800) and other COVID-19 phase four response legislation with Congressional staff.
Discuss Medicare Advance Payment forgiveness with Congressional staff, advocated for H.R. 7292 (support).
Support a delay of Medicaid DSH reimbursement cuts in COVID-19 response package and a delay or repeal of the Medicaid Fiscal Accountability Regulation.
Discuss increased Federal Medical Assistance Percentages (support) and increased funding for state and local governments (support) with Congressional staff.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryan |
Yuhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Discuss proposed appropriations language related to OPTN/UNOS liver allocation reforms with Congressional staff.
Support the inclusion of funding for hospital infrastructure and workforce programs in appropriations legislation.
Support for the inclusion of provisions to delay the Medicaid DSH cuts in appropriations legislation.
Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Support direct funding for health care providers treating COVID-19 patients, including funding through the Hospital Preparedness Program.
Support funding and efforts to ensure health care providers have access to essential materials, such as PPE, for COVID-19 response and readiness.
Advocate for direct Federal funding for state and local governments during the COVID-19 crisis.
Support graduate medical education funding through the Medicare program, including support for the Resident Physician Shortage Reduction Act (S. 348/H.R. 1763) and the Opioid Workforce Act (H.R. 3414/S. 2439) and its inclusion in appropriations legislative.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryan |
Yuhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital (DSH) cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Support direct funding for health care providers treating COVID-19 patients, including funding through the Hospital Preparedness Program.
Support funding and efforts to ensure health care providers have access to essential materials, such as PPE, for COVID-19 response and readiness.
Advocate for changes to indirect medical education payments to account for COVID-19 response efforts.
Advocate for direct Federal funding for state and local governments during the COVID-19 crisis.
Discuss the distribution methodology for the Public Health and Social Services Emergency Fund with Congressional staff.
Discuss issues related to Medicare accelerated payments with Congressional staff.
Discuss legislative priorities with Congressional staff: a delay of cuts to Medicaid DSH funding (support), site-neutral policies (oppose), 340B drug discount program (support), expanding federal graduate medical education programs (support), funding to address the opioid crisis (support), funding for hospital infrastructure (support), the Affordable Care Act (support), and liver allocation reforms (support).
Discuss the need to reform the United States' liver allocation system with Congressional staff/members.
Support graduate medical education funding through the Medicare program, including support for the Resident Physician Shortage Reduction Act (S. 348/H.R. 1763) and the Opioid Workforce Act (H.R. 3414/S. 2439).
Discuss technical assistance regarding the Opioid Workforce Act (H.R. 3414/S. 2439) with committee staff.
Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff.
Support surprise billing legislation reform and work with committee and Congressional staff on a range of issues. Discussed several bills including: Protecting People from Surprise Medical Bills Act (H.R. 3502), Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630) and Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826).
Discuss the Medicare GME program, including issues related to oversight and transparency, with congressional staff.
Discuss provisions in the CARES Act (H.R. 748) related to health care provider liability and immunity with Congressional staff.
Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff.
Discuss issues related to telehealth and HIT with congressional staff.
Discuss drug shortages related to the COVID-19 crisis with Congressional and Administration staff.
Discuss the HEROES Act (H.R. 6800) and other COVID-19 phase four response legislation with Congressional staff.
Discuss disbursements from the Public Health and Social Services Emergency Fund with Congressional staff.
Discuss Medicare Advance Payment forgiveness with Congressional staff.
Discuss supply chain issues, including PPE and ventilators, with Congressional staff.
Support a delay of Medicaid DSH reimbursement cuts in COVID-19 response package and a delay or repeal of the Medicaid Fiscal Accountability Regulation.
Discuss increased Federal Medical Assistance Percentages (support) and increased funding for state and local governments (support) with Congressional staff.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ryan |
Yuhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |